Loading
Inflammasome and Immune Disorders · Journal article
Seminars in Immunology · August 8, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review article outlining the dual and context-dependent roles of the IL-1 cytokine system in cancer pathogenesis and immune control. The source describes mechanistic concepts—including how IL-1α and IL-1β can both promote cancer cell proliferation and pro-inflammatory microenvironments and simultaneously activate anti-tumor immunity—without presenting new experimental or clinical trial data to test these relationships.
Journal article. Conceptual; not applicable to a specific study population..
IL-1α and IL-1β can directly promote cancer cell proliferation, survival, and plasticity, and contribute to pro-inflammatory environment promoting tissue remodeling, cellular stress, and genomic instability. IL-1 acts as a lymphoproliferative and activating molecule in innate and adaptive immune responses, contributing to anti-tumor immune-mediated responses. IL-1 family members play non-redundant roles and may exhibit dual, context-dependent roles in cancer—driving both pro- and anti-tumor processes depending on cellular target and context.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review provides a conceptual framework for understanding IL-1 biology in cancer but does not present clinical trial results or quantitative evidence that would directly inform treatment decisions. Clinicians should recognize that IL-1 targeting strategies may have competing effects and require context-specific evaluation.
A narrative review synthesizing mechanistic understanding of IL-1 system roles in cancer initiation, progression, and immunity; raises questions about dual and context-dependent functions rather than testing a specific clinical or experimental hypothesis with quantitative evidence.
This review provides a conceptual framework for understanding IL-1 biology in cancer but does not present clinical trial results or quantitative evidence that would directly inform treatment decisions. Clinicians should recognize that IL-1 targeting strategies may have competing effects and require context-specific evaluation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Inflammation is a pathogenetic driver of several pathological conditions, including cancer. The tumor microenvironment, which includes cellular, molecular, and structural components, is an essential component of cancer, involved in tumor promoting or controlling processes. In particular, inflammatory players contribute to the establishment of a tumor-promoting microenvironment, which affects all stages of tumor development, from initiation to metastasis, as well as response to therapy. The IL-1 system includes two large sets of structurally related ligands and receptors, with agonist or regulatory activity, playing non-redundant roles in inflammation and immunity. Each of them has specific functions in tissue homeostasis, inflammation, innate and adaptive immune responses, and potentially contributes to processes related to carcinogenesis and metastasis, or immune-mediated control of cancer cells. Depending on the context and cellular target, IL-1 family members may play dual roles in cancer, driving both pro- or anti-tumor processes. IL-1α and IL-1β can directly promote cancer cell proliferation, survival, and plasticity, in addition to contribute to the establishment of a pro-inflammatory environment that promotes tissue remodeling, cellular stress responses, and genomic instability. On the other hand, IL-1 is a lymphoproliferative and activating molecule in innate and adaptive responses, thus contributing to anti-tumor immune mediated responses. In addition, members of the IL-1 system act as regulators of mechanisms involved in cancer, including emergency hematopoiesis, trained immunity, and metabolism. Here, we will provide an overview of the IL-1 system in cancer and discuss the functional complexity of IL-1 family cytokines, which orchestrate both protective and pro-tumorigenic responses, by directly acting on cancer cells and by driving environmental stimuli which indirectly act on cancer cells.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.